What is Arcellx?
Arcellx is at the forefront of developing adaptive and controllable cell therapies designed to address the complex treatment needs of patients with cancer and autoimmune diseases. Operating at the clinical stage, the company leverages a proprietary platform technology that enables precise engineering and regulation of cellular therapeutics, aiming for enhanced safety profiles and improved therapeutic outcomes. The core innovation lies in creating cell therapies that can be dynamically controlled and adjusted during treatment, offering clinicians unprecedented flexibility and addressing a critical gap in current cell therapy applications. This adaptive capability is poised to expand the clinical utility and patient access to advanced cell therapies.
How much funding has Arcellx raised?
Arcellx has raised a total of $284M across 3 funding rounds:
Series B
$85M
Series C
$75M
Stock Offering
$124M
Series B (2019): $85M with participation from Mirae Asset Capital Co,Ltd, Novo Holdings, Takeda Ventures, Mirae Asset Global Investments, Aju IB, Clough Capital Partners, SR One Limited, LG Technology Ventures, NEA, Quan Capital, and JVC Investment Partners
Series C (2021): $75M led by Asymmetry, Samsara BioCapital, Soleus Capital, Caas Capital Management, Clough Capital, LG Tech, Cambrian BioPharma, S.R. One, Terra Magnum Capital Partners, Sixty Degree, Novo Holdings, Adage, Surveyor Capital, New Enterprise Associates, Takeda Ventures, Suvretta, and CAM Capital
Stock Issuance/Offering (2022): $124M, investors not publicly disclosed
Key Investors in Arcellx
Novo Holdings
Novo Holdings is a prominent investment company with a significant focus on the life sciences sector, known for backing innovative biotechnology and healthcare companies.
Takeda Ventures
Takeda Ventures is the corporate venture arm of Takeda Pharmaceutical Company, investing in early-stage companies with transformative technologies in areas aligned with Takeda's therapeutic focus.
SR One Limited
SR One is a transatlantic venture capital firm specializing in early and growth-stage life sciences companies, providing strategic support and capital to advance novel therapeutics.
What's next for Arcellx?
With substantial enterprise-level funding and a recent strategic investment, Arcellx is well-positioned for accelerated growth and pipeline advancement. The company's focus on a controllable cell therapy platform suggests a strategic direction towards overcoming the limitations of existing cell therapies, potentially opening new therapeutic avenues. Future developments will likely involve progressing its lead candidates through clinical trials, further validating its platform's efficacy and safety, and potentially exploring strategic partnerships to broaden market reach and manufacturing capabilities. The company's ambition to democratize access to advanced cell therapies indicates a long-term vision for significant market impact.
See full Arcellx company page
